EXEL Stock Forecast: Exelixis, Inc. Price Predictions for 2026-2027
The 17 Wall Street analysts covering Exelixis, Inc. hold a median 12-month price target of $59 — -8.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 100 of 100 as at 21 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Exelixis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (75): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
EXEL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EXEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −8.7% from it.
Of the 20 most recent actions, 16 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Morgan Stanley | Maintains | Equal-Weight | $60 → $57 |
| 5 Nov 2026 | Leerink Partners | Maintains | Market Perform | $55 → $58 |
| 2 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $56 → $78 |
| 30 Oct 2026 | Barclays | Maintains | Equal-Weight | $49 → $54 |
| 30 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | $53 → $60 |
| 30 Oct 2026 | RBC Capital | Maintains | Sector Perform | $51 → $58 |
| 30 Oct 2026 | TD Cowen | Maintains | Buy | $55 → $76 |
| 30 Oct 2026 | Truist Securities | Maintains | Hold | $54 → $60 |
| 19 Oct 2026 | Citizens | Maintains | Market Outperform | $55 → $65 |
| 9 Oct 2026 | RBC Capital | Maintains | Sector Perform | $45 → $51 |
| 8 Oct 2026 | RBC Capital | Maintains | Sector Perform | $46 → $45 |
| 7 Oct 2026 | Truist Securities | Maintains | Hold | $52 → $54 |
| 19 Aug 2026 | BMO Capital | Initiates | Market Perform | $54 |
| 6 Aug 2026 | Stifel | Maintains | Hold | $47 → $51 |
| 6 Aug 2026 | Truist Securities | Maintains | Hold | $56 → $52 |
| 23 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $50 → $53 |
| 14 July 2026 | Barclays | Maintains | Equal-Weight | $45 → $49 |
| 13 July 2026 | Wells Fargo | Maintains | Equal-Weight | $40 → $49 |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | $43 → $46 |
| 7 July 2026 | Truist Securities | Maintains | Hold | $54 → $56 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EXEL.
This page is one stock. Monday covers all of them.
EXEL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
EXEL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Exelixis, Inc. returned +54.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
EXEL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 20.0×
- Price / sales
- 6.5×
- Price / book
- 8.9×
- EV / EBITDA
- 14.9×
Cheaper than 45% of US stocks
Cheaper than 17% of US stocks
Cheaper than 9% of US stocks
Cheaper than 35% of US stocks
- Revenue growth (YoY)
- 10.2%
- Earnings growth (YoY)
- 12.7%
- Gross margin
- 96.7%
- Operating margin
- 40.2%
- Net margin
- 35.4%
Higher than 54% of US stocks
Higher than 52% of US stocks
Higher than 99% of US stocks
Higher than 93% of US stocks
Higher than 92% of US stocks
- Return on equity
- 44.3%
- Return on assets
- 23.5%
- Dividend yield
- —
Higher than 92% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Exelixis, Inc. has a market value of $16.1B and an enterprise value of $15.3B.
Revenue in the twelve months to 30 June 2026: $2.4B. The latest quarter grew 10.6% year on year.
Net income over the same four quarters: $860.6M, a 35.3% net margin.
Diluted earnings per share, trailing twelve months: $3.18.
Free cash flow in the twelve months to 30 June 2026: $1.2B.
Exelixis, Inc. spent $1.1B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 20.0×; forward P/E: 15.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Exelixis, Inc. employs 1,077 people — $2.3M of revenue per employee.
Data provided by Twelve Data
EXEL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at EXEL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Exelixis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about EXEL
What is the EXEL stock price forecast for 2026-2027?
The 17 Wall Street analysts covering Exelixis, Inc. have a median 12-month price target of $59, with estimates ranging from $41 to $78. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is EXEL stock a buy right now?
Of the 17 analysts covering Exelixis, Inc., 6 rate it a Buy, 10 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Exelixis, Inc. 100 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank EXEL?
As at 21 Nov 2026, Exelixis, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
Will EXEL stock go up?
No one can know that. What the data says: the median 12-month target from 17 analysts implies -8.7% from the last close, and Ticker Nerd's factor model ranks Exelixis, Inc. 100 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the EXEL stock forecast for 2030?
No analyst covering Exelixis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EXEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $78 over the next 12 months.
How has EXEL stock performed over the past year?
Exelixis, Inc. returned +54.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Exelixis, Inc. do?
Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in clinical practice.
About Exelixis, Inc.
Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in clinical practice. Exelixis also advances a broader pipeline of small-molecule and biotherapeutic candidates aimed at expanding treatment options in solid tumors and other oncology settings. In addition to internal drug development, the company works through collaborations to support research, development, and commercialization activities. Based in Alameda, California, Exelixis plays a significant role in the cancer treatment market by combining approved products with an active development pipeline focused on targeted oncology medicines.
CEO Dr. Michael M. Morrissey Ph.D. · 1,077 employees · United States · https://www.exelixis.com